ClinicalTrials.Veeva

Menu

The IRESSA Novel Head and Neck Chemotherapy Evaluation Study

AstraZeneca logo

AstraZeneca

Status and phase

Completed
Phase 2

Conditions

Squamous Cell Cancer
Cancer of Head and Neck

Treatments

Drug: gefitinib
Drug: 5-flourouracil
Drug: cisplatin

Study type

Interventional

Funder types

Industry

Identifiers

NCT00255476
1839IL/0544

Details and patient eligibility

About

The purpose of this study is to compare the objectie tumour response rate between the cisplatin/5FU and cisplatin/5FU plus ZD1839 combination

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Provision of written informed consent
  • Patients with histologically proven primary SCCHN
  • Aged 18 or over

Exclusion criteria

  • Patients eligible for surgery with curative intent
  • Other co-existing malignancies diagnosed within the last 5 years with the exception of basal cell carcinoma or cervical cancer in situ
  • Exclude UCNT

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

None (Open label)

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems